Sanofi to Continue Development of Kadmon’s dcSSc Therapy After Buyout

Sanofi to Continue Development of Kadmon’s dcSSc Therapy After Buyout

305445

Sanofi to Continue Development of Kadmon’s dcSSc Therapy After Buyout

Sanofi has entered into a merger agreement with Kadmon, which is developing belumosudil (KD025), an oral investigational treatment for people with the diffuse cutaneous form of systemic sclerosis (dcSSc). Belumosudil, sold under the brand name Rezurock, was recently approved for patients, 12 years and older, with chronic graft-versus-host disease (cGVHD) — a condition characterized by an attack by transplanted immune cells on the host patient’s cells, causing inflammation and fibrosis (scarring) in multiple tissues. The…

You must be logged in to read/download the full post.